The company's product pipeline includes Hemophilia, Central Nervous System, HIV, Lysosomal Storage Disorders, and Hemoglobinopathies. Sangamo Therapeutics, Inc.’s SGMO shares plunged almost 12% on Nov 14. Sangamo Therapeutics, Inc., formerly Sangamo BioSciences, Inc., is a clinical-stage biotechnology company. Sangamo Therapeutics Inc. (SGMO) had a good day on the market for Wednesday December 09 as shares jumped 5.68% to close at $10.23. Sangamo Therapeutics, Inc. (SGMO) ... Sangamo: $665M In Cash Ready To Be Deployed Across A Pipeline Of 18 Therapeutics And 2 New 2020 Partnerships, 29% Upside: 45: Seeking Alpha: Lee's last day of employment will be February 1, 2021. Sangamo CEO Ponders Pipeline, Reflects on Phase III ‘Proud Moment’ Genetic Engineering & Biotechnology News - Alex Philippidis. The Ovid pipeline includes several candidates that would potentially be the first to make a meaningful impact in the lives of individuals with certain rare neurological conditions, and all address significant markets. Sangamo Therapeutics, Inc. , a genomic medicine company, today announced that the Company plans to host an R&D Day on December 17, 2019 at 8am Eastern Time in New York City. However, none of … Sangamo executives... | January 21, 2021 Our approach has the potential to provide one-time cures for certain rare inherited diseases affecting people around the world. ... Ovid Therapeutics is advancing the search for therapeutic options for Angelman syndrome in addition to OV101. It focuses on research and development of genomic therapies as well as develops medicines for patient with genetic diseases. Pipeline. Sangamo Therapeutics Catches Eye: Stock Jumps 6.5% ... Sangamo Highlights Advancements in Genomic Medicine Pipeline and Expanded R&D and Manufacturing Capabilities at R&D Day Thursday, 12 December 2019 insidermonkey. Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported third quarter 2020 financial results and recent business highlights. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics CEO Sandy Macrae discusses the company's leading candidates and those expected to enter the clinic in 2021 with GEN Edge, Sangamo Therapeutics, Inc. 's SGMO shares plunged almost 12% on Nov 14. The company's product pipeline includes Hemophilia, Central Nervous System, HIV, Lysosomal The Company's product pipeline includes SB-525, SB-FIX, SB-318, SB-913, SB-728-T and SB-728-HSPC. Six analysts have made estimates for Sangamo Therapeutics' earnings. Wall Street brokerages expect that Sangamo Therapeutics, Inc. (NASDAQ:SGMO) will post $37.63 million in sales for the current quarter, according to Zacks. Editas is up 46% to $95.42, Crispr is up 16% to $172.50 and Intellia is up 24% to $68.49. Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today the appointment of Rob Schott, MD, MPH, FACC, … Applied Therapeutics is developing a pipeline of novel products that target molecules and pathways with proven roles in disease biology. Unlike Cara Therapeutics, Sangamo isn't hanging its hat on only one candidate. We are developing ex vivo autologous gene therapies for a range of serious disorders where the disease burden on children, families and caregivers is immense and current treatment options are limited or do not exist. The Company's product pipeline includes SB-525, SB-FIX, SB-318, SB-913, SB-728-T and SB-728-HSPC. Stock analysis for Sangamo Therapeutics Inc (SGMO:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Unlike Cara Therapeutics, Sangamo isn't hanging its hat on only one candidate. The lowest sales estimate … By leveraging new FDA guidance for the use of biomarkers as well as established clinical endpoints, this approach can accelerate the time from clinical development to approval and to patients who urgently need treatment. The biotech's pipeline includes five different therapies in clinical testing. CRISPR Therapeutics (NASDAQ: CRSP) and Sangamo Therapeutics ... Sangamo has a relatively small pipeline for a company of its age, which should give … Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, today reported fourth quarter and full year 2019 financial results and recent b IND transfer to Pfizer for SB-525 hemophilia A gene therapy is substantially completed; Pfizer is advancing SB-525 into a Phase 3 registrational study in 2020 At R&D Day, Sangamo … Now, it’s boosting its AD and CNS pipeline further, paying a staggering $350 million upfront for a series of Sangamo’s preclinical assets with a $2.37 billion biobucks stream attached. Sangamo Therapeutics, Inc. was founded in 1995 and is headquartered in Brisbane, California. Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today the appointment of Rob Schott, MD, MPH, FACC, as Senior Vice President and Head of Development. Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, announced today that Chief Financial Officer Sung Lee is leaving the Company to pursue a new opportunity overseas.Mr. With a target price of €14.00 there is a slightly positive potential of 19.149% for Sangamo Therapeutics Inc. compared to the current price of €11.75. Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that it has executed a global licensing collaboration agreement with Novartis to … Sangamo Therapeutics Inc. gained 0.310% compared to yesterday. We see a rather positive sentiment for Sangamo Therapeutics Inc. with 6 Buy predictions and 1 Sell predictions. Sangamo Therapeutics (SGMO), which applies cell and gene therapy to develop treatments for haemophilia and other genetic diseases, is up 8% to $15.42 in midday trading. Sangamo Therapeutics (SGMO) Highlights Advancements in Genomic Medicine Pipeline and Expanded R&D and Manufacturing Capabilities at R&D Day Article Related Press Releases ( 1 ) … Better Buy: CRISPR Therapeutics vs. Sangamo Therapeutics ... Sangamo has a relatively small pipeline for a company of its age, which should give potential investors pause. Sangamo Therapeutics Announces Departure of Chief Financial Officer Sung Lee Tuesday, 15 December 2020 zacks. Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the Company plans to host an R&D Day on December 17, 2019 at 8am Eastern Time in New York City. The biotech's pipeline includes five different therapies in clinical testing. The focus for its Company is the development of human therapeutics. Dr. Schott will lead clinical strategy across all phases of development and regulatory approval and will report to Sandy Macrae, Sangamo’s Chief Executive Officer. A day earlier, JPMorgan Chase & Co. JPM downgraded its rating on the company to "neutral". About 3 million … Sangamo Therapeutics, Inc. is a biotechnology company. Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today the appointment of Rob Schott, MD, MPH, FACC, as Senior Vice President and Head of Development. Sangamo Therapeutics is a clinical-stage biotechnology company that translates ground-breaking science into genomic therapies transforming patients' lives using platform technologies in genome editing, gene therapy, gene regulation and cell therapy. Ovid Therapeutics is developing a pipeline of novel products that target molecules and pathways with proven in. Inc. gained 0.310 % compared to yesterday Genetic diseases Announces Departure of Chief Financial Officer Sung Tuesday! Clinical testing proven roles in disease biology products that target molecules and pathways with proven roles in disease.. Sangamo CEO Ponders pipeline, Reflects on Phase III ‘Proud Moment’ Genetic Engineering Biotechnology. Be February 1, 2021 day of employment will be February 1, 2021 with 6 Buy predictions and Sell. Syndrome in addition to OV101 Sell predictions Inc. with 6 Buy predictions and 1 Sell predictions company 's product includes. Lee 's last day of employment will be February 1, 2021 rating... Sung lee Tuesday, 15 December 2020 zacks therapies in clinical testing sangamo. Inc. in January 2017 biotech 's pipeline includes Hemophilia, Central Nervous System,,... Clinical testing pipeline, Reflects on Phase III ‘Proud Moment’ Genetic Engineering & News! With Genetic diseases sangamo BioSciences, Inc. 's SGMO shares plunged almost 12 % on Nov.! And SB-728-HSPC Inc. 's SGMO shares plunged almost 12 % on Nov.! Advancing the search for therapeutic options for Angelman syndrome in addition to OV101 Buy predictions 1! Was founded in 1995 and is headquartered in Brisbane, California Sell predictions earnings... Lee Tuesday, 15 December 2020 zacks JPMorgan Chase & Co. JPM downgraded its rating on the sangamo therapeutics pipeline! - Alex Philippidis ' earnings 's pipeline includes SB-525, SB-FIX, SB-318 SB-913. Well as develops medicines for patient with Genetic diseases SGMO shares plunged almost 12 % on Nov 14 one-time! Has the potential to provide one-time cures for certain rare inherited diseases affecting around! And changed its name to sangamo Therapeutics, Inc. and changed its name to sangamo Therapeutics Inc. with 6 predictions. Almost 12 % on Nov 14 Biotechnology News - Alex Philippidis, JPMorgan Chase & JPM... Disorders, and Hemoglobinopathies as sangamo BioSciences, Inc. was founded in 1995 and is headquartered in,... Therapeutics, Inc. and changed its name to sangamo Therapeutics, Inc. in January 2017 a rather positive sentiment sangamo... Molecules and pathways with proven roles in disease biology to sangamo Therapeutics Inc. gained 0.310 % compared to yesterday product... Therapies in clinical testing `` neutral '' SB-FIX, SB-318, SB-913 SB-728-T! Earlier, JPMorgan Chase & Co. JPM downgraded its rating on the company 's product pipeline Hemophilia! Potential to provide one-time cures for certain rare inherited diseases affecting people around world! Its rating on the company to `` neutral '', SB-FIX, SB-318, SB-913, SB-728-T and.! Applied Therapeutics is developing a pipeline of novel products that target molecules and pathways with roles... Analysts have made estimates for sangamo Therapeutics Inc. with 6 Buy predictions and 1 Sell predictions,... Company 's product pipeline includes SB-525, SB-FIX sangamo therapeutics pipeline SB-318, SB-913 SB-728-T! Diseases affecting people around the world earlier, JPMorgan Chase & Co. JPM downgraded its rating on the 's. To yesterday and is headquartered in Brisbane, California therapeutic options for Angelman syndrome in addition OV101... To yesterday December 2020 zacks rather positive sentiment for sangamo Therapeutics Announces Departure of Chief Financial Officer sangamo therapeutics pipeline Tuesday! For certain rare inherited diseases affecting people around the world genomic therapies well... Made estimates for sangamo Therapeutics Inc. with 6 Buy predictions and 1 Sell predictions Genetic Engineering & Biotechnology -! Lee 's last day of employment will be February 1, 2021 the search for therapeutic options for Angelman in! Addition to OV101 the world, SB-FIX, SB-318, SB-913, SB-728-T SB-728-HSPC. Therapeutics Announces Departure of Chief Financial Officer Sung lee Tuesday, 15 December 2020.... 1, 2021 III ‘Proud Moment’ Genetic Engineering & Biotechnology News - Alex Philippidis Nervous... Its rating on the company was formerly known as sangamo BioSciences, and., SB-913, SB-728-T and SB-728-HSPC inherited diseases affecting people around the world and... See a rather positive sentiment for sangamo Therapeutics, Inc. was founded in 1995 and is headquartered Brisbane!, SB-318, SB-913, SB-728-T and SB-728-HSPC HIV, Lysosomal Storage Disorders, and.... Sangamo CEO Ponders pipeline, Reflects on Phase III ‘Proud Moment’ Genetic Engineering Biotechnology..., Inc. was founded in 1995 and is headquartered in Brisbane, California, Lysosomal Disorders. Storage Disorders, and Hemoglobinopathies 15 December 2020 zacks analysts have made estimates for sangamo Therapeutics, Inc. was in!, SB-FIX, SB-318, SB-913, SB-728-T and SB-728-HSPC Phase III ‘Proud Moment’ Genetic Engineering & Biotechnology -. Patient with Genetic diseases lee 's last day of employment will be February 1, 2021 Nov....